Challenging the anticoagulant paradigm?

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 1, 2016, Pages 134-136

  Ten Cate, H ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; D DIMER; HEPARIN; HIRUDIN; PROTHROMBIN; THROMBIN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BRAIN HEMORRHAGE; DRUG SAFETY; HUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ANTICOAGULANTS; HUMANS;

EID: 84954496909     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13203     Document Type: Note

References (18)

1. Gómez-Outes A, Suárez-Gea ML, Calvo-Rojas G, Lecumberri R, Rocha E, Pozo-Hernández C, Terleira-Fernández AI, Vargas-Castrillón E. Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol 2012; 9: 83-104.
2. Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, et al. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015; 10: 997-1009.
3. Ghanny S, Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. Curr Opin Hematol 2013; 20: 430-6.
4. Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 2015; 113: 1370-7.
5. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI; XI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 15: 232-40.
6. James P, Salomon O, Mikovic D, Peyvandi F. Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia 2014; 20(Suppl. 4): 71-5.
7. Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39: 621-31.
8. Kenne E, Nickel KF, Long AT, Fuchs TA, Stavrou EX, Stahl FR, Renné T. Factor XII: a novel target for safe prevention of thrombosis and inflammation. J Intern Med 2015; doi:10.1111/joim.12430. [Epub ahead of print]
9. Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost 2014; 1: 570-4.
10. Baglin TP, Langdown J, Frasson R, Huntington JA. Discovery and characterization of an antibody directed against exosite I of thrombin. J Thromb Haemost. 2015; doi: 10.1111/jth.13171 .[Epub ahead of print]
11. Du VX, Kelchtermans H, de Groot PG, de Laat B. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res 2013; 132: 319-26.
12. Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res 2015; 135: 388-93.
13. Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial. J Thromb Haemost 2014; 12: 1401-12.
14. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011; 9: 1687-704.
15. Chuang YC, Lin YS, Liu HS, Yeh TM. Molecular mimicry between dengue virus and coagulation factors induces antibodies to inhibit thrombin activity and enhance fibrinolysis. J Virol 2014; 88: 13759-68.
16. Bock PE, Panizzi P, Verhamme IM. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 2007; 5(Suppl. 1): 81-94.
17. Kretz CA, Cuddy KK, Stafford AR, Fredenburgh JC, Roberts R, Weitz JI. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions. Thromb Haemost 2010; 103: 83-93.
18. http://www.businessweekly.co.uk/news/biomedtech/janssen-snaps-cambridge-%E2%80%98miracle%E2%80%99-antibody-startup#sthash.ARNLWhvv.dpuf.